A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
=== Diet === Adapting nutritional intake can help to prevent and treat overtraining. Athletes in different fields will emphasize different proportional nutrition factors on the diet mainly including proteins, carbohydrates and fats. The diet includes a calorie intake that at least matches expenditure, ideally forming a suitable macronutrient ratio. During the recovery process, extra calories from diets may help the body speed the recovery. Keeping the body nourished with a balanced diet and hydrated with an adequate supply of water are both important for a successful recovery. Finally, addressing vitamin deficiencies with improved diet and/or nutritional supplements has been proposed as a way to speed up recovery.
==== 1300–1399 ==== Concession Statements (Prescribed Information) Regulations 1993 (S.I. 1993/1300) Gipsy Encampments (City of Hereford) Order 1993 (S.I. 1993/1301) South Wales Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1302) Dyfed-Powys Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1303) Seed Potatoes (Fees) (Scotland) Regulations 1993 (S.I. 1993/1311) Eastwood and East Kilbride Districts (Busby) Boundaries Amendment Order 1993 (S.I. 1993/1312) Margate Pier and Harbour Revision Order 1992 (SI 1993/1313) Integrated Administration and Control System Regulations 1993 (S.I. 1993/1317) Lewisham and Southwark (London Borough Boundaries) Order 1993 (S.I. 1993/1318) Greater London and Surrey (County and London Borough Boundaries) (No.3) Order 1993 (S.I. 1993/1319) Plant Health (Great Britain) Order 1993 (S.I. 1993/1320) Health and Safety (Fees) Regulations 1993 (S.I. 1993/1321) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass and Slip Road) Order 1993 (S.I. 1993/1322) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass) (Detrunking) Order 1993 (S.I. 1993/1323) Post Office (Abolition of Import Restrictions) Regulations 1993 (S.I. 1993/1324) Fishing Vessels (Safety Improvements) (Grants) Scheme 1993 (S.I. 1993/1325) Insurance Companies (Cancellation) Regulations 1993 (S.I. 1993/1327) Diseases of Animals (Therapeutic Substances) (Revocation) Order 1993 (S.I. 1993/1331) Foot-and-Mouth Disease (Sera and Glandular Products) (Revocation) Order 1993 (S.I.
Potassium alum was the major immunologic adjuvant used to increase the efficacy of vaccines, and has been used since the 1920s. But it has been almost completely replaced by aluminium hydroxide and aluminium phosphate in commercial vaccines. Alum may be used in depilatory waxes used for the removal of body hair or applied to freshly waxed skin as a soothing agent.
Sources: en.wikipedia.org
=== Commercial Engineers & Body Builders Company Ltd (CEBBCO) === Commercial Engineers & Body Builders Company Ltd (CEBBCO), a Madhya Pradesh based manufacturer of tipplers, trailers, and specialized defence vehicles, was acquired by Jupiter Wagons Limited in a buyout of its organization in 2019 under a National Company Law Tribunal (NCLT) governed stressed asset sale. JWL latter on 29 June 2022, announced its reverse merger with CEBBCO. Therefore, with this, the company completed its listing on the bourses.
Afluria (influenza vaccine) -- Argentina, Peru, South Africa, Spain, US Enzira—in various different markets Fluvax—in various different markets Nilgrip—in various different markets Afluria Quadrivalent (influenza vaccine) -- Australia, Canada, New Zealand, US Afluria Quad—in various different markets Afluria Tetra—in various different markets Agrippal (influenza vaccine) -- Argentina, Austria, Brazil, Canada, Chile, Colombia, Germany, Italy, Mexico, Spain, Thailand Agriflu—in various different markets Begripal—in various different markets Chiroflu—in various different markets Fluazur—in various different markets Sandovac—in various different markets Audenz (influenza A (H5N1) vaccine) -- US Fluad (influenza vaccine) -- Argentina, Austria, Australia, Brazil, Canada, Denmark, Germany, Italy, Spain, Switzerland, UK, US Chiromas—Spain Fluad Pediatric (influenza vaccine) -- Canada Flucelvax Quadrivalent (influenza vaccine) -- Germany, Italy, Spain, UK, US Q-VAX (Coxiella burnetii vaccine) -- Australia Rapivab (peramivir) -- Australia, US Antivenoms: (Australia)
== Political impact == In Britain the Liberal Party objected to, and later opposed, the Boer War. Later, Jameson became Prime Minister of the Cape Colony (1904–08) and one of the founders of the Union of South Africa. He was made a baronet in 1911 and returned to England in 1912. On his death in 1917, he was buried next to Cecil Rhodes and the 34 BSAC soldiers of the Shangani Patrol (killed in 1893 in the First Matabele War) in the Matobos Hills, near Bulawayo.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.